TY - JOUR
T1 - The S/T-Rich Motif in the DNAJB6 Chaperone Delays Polyglutamine Aggregation and the Onset of Disease in a Mouse Model
AU - Kakkar, Vaishali
AU - Månsson, Cecilia
AU - de Mattos, Eduardo P.
AU - Bergink, Steven
AU - van der Zwaag, Marianne
AU - van Waarde, Maria A.W.H.
AU - Kloosterhuis, Niels J.
AU - Melki, Ronald
AU - van Cruchten, Remco T.P.
AU - Al-Karadaghi, Salam
AU - Arosio, Paolo
AU - Dobson, Christopher M.
AU - Knowles, Tuomas P.J.
AU - Bates, Gillian P.
AU - van Deursen, Jan M.
AU - Linse, Sara
AU - van de Sluis, Bart
AU - Emanuelsson, Cecilia
AU - Kampinga, Harm H.
N1 - Publisher Copyright:
© 2016 Elsevier Inc.
PY - 2016/4/21
Y1 - 2016/4/21
N2 - Expanded CAG repeats lead to debilitating neurodegenerative disorders characterized by aggregation of proteins with expanded polyglutamine (polyQ) tracts. The mechanism of aggregation involves primary and secondary nucleation steps. We show how a noncanonical member of the DNAJ-chaperone family, DNAJB6, inhibits the conversion of soluble polyQ peptides into amyloid fibrils, in particular by suppressing primary nucleation. This inhibition is mediated by a serine/threonine-rich region that provides an array of surface-exposed hydroxyl groups that bind to polyQ peptides and may disrupt the formation of the H bonds essential for the stability of amyloid fibrils. Early prevention of polyQ aggregation by DNAJB6 occurs also in cells and leads to delayed neurite retraction even before aggregates are visible. In a mouse model, brain-specific coexpression of DNAJB6 delays polyQ aggregation, relieves symptoms, and prolongs lifespan, pointing to DNAJB6 as a potential target for disease therapy and tool for unraveling early events in the onset of polyQ diseases. Kakkar et al. show that DNAJB6 is a chaperone that inhibits early steps in the formation of polyQ amyloid fibrils. An S/T-rich region in DNAJB6 is crucial for this function. In a polyQ mouse model, the inhibitory effects of DNAJB6 delay disease onset and increase lifespan.
AB - Expanded CAG repeats lead to debilitating neurodegenerative disorders characterized by aggregation of proteins with expanded polyglutamine (polyQ) tracts. The mechanism of aggregation involves primary and secondary nucleation steps. We show how a noncanonical member of the DNAJ-chaperone family, DNAJB6, inhibits the conversion of soluble polyQ peptides into amyloid fibrils, in particular by suppressing primary nucleation. This inhibition is mediated by a serine/threonine-rich region that provides an array of surface-exposed hydroxyl groups that bind to polyQ peptides and may disrupt the formation of the H bonds essential for the stability of amyloid fibrils. Early prevention of polyQ aggregation by DNAJB6 occurs also in cells and leads to delayed neurite retraction even before aggregates are visible. In a mouse model, brain-specific coexpression of DNAJB6 delays polyQ aggregation, relieves symptoms, and prolongs lifespan, pointing to DNAJB6 as a potential target for disease therapy and tool for unraveling early events in the onset of polyQ diseases. Kakkar et al. show that DNAJB6 is a chaperone that inhibits early steps in the formation of polyQ amyloid fibrils. An S/T-rich region in DNAJB6 is crucial for this function. In a polyQ mouse model, the inhibitory effects of DNAJB6 delay disease onset and increase lifespan.
UR - http://www.scopus.com/inward/record.url?scp=84963566241&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84963566241&partnerID=8YFLogxK
U2 - 10.1016/j.molcel.2016.03.017
DO - 10.1016/j.molcel.2016.03.017
M3 - Article
AN - SCOPUS:84963566241
SN - 1097-2765
VL - 62
SP - 272
EP - 283
JO - Molecular Cell
JF - Molecular Cell
IS - 2
ER -